Segment Reporting - Segment information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Segment Reporting
Grant and award revenue	$ 4,904	$ 5,174
Total research and development expenses	23,717	34,426
Total general and administrative expenses	12,409	13,184
Impairment expense	5,412
Total operating expenses	41,538	47,610
Operating loss	(36,634)	(42,436)
Other income (expense), net	(137,165)	23,520
Net loss	(173,799)	(18,916)
Single Reportable Segment
Segment Reporting
Grant and award revenue	4,904	5,174
Expenses not allocated by projects	2,696	2,408
Total external research and development expenses	5,002	13,696
Research and development personnel expenses	9,199	10,764
Other research and development expenses	9,516	9,966
Total research and development expenses	23,717	34,426
General and administrative personnel expenses	4,897	4,935
Other general and administrative expenses	7,512	8,249
Total general and administrative expenses	12,409	13,184
Impairment expense	5,412
Total operating expenses	41,538	47,610
Operating loss	(36,634)	(42,436)
Other income (expense), net	(137,165)	23,520
Net loss	(173,799)	(18,916)
Single Reportable Segment | AP-PA02: Non-Cystic Fibrosis Bronchiectasis
Segment Reporting
External research and development expenses	114	6,840
Single Reportable Segment | AP-PA02: Cystic Fibrosis
Segment Reporting
External research and development expenses	33	236
Single Reportable Segment | AP-SA02: Bacteremia
Segment Reporting
External research and development expenses	2,157	4,177
Single Reportable Segment | AP-SA02: Prosthetic Joint Infection
Segment Reporting
External research and development expenses	$ 2	$ 35